Proteon Therapeutics has failed another phase 3 chronic kidney disease trial. The latest failure raised significant doubts about the future of vonapanitase, wiping 85% off Proteon’s stock price and ...

Proteon Therapeutics, Inc. PRTO announced disappointing top-line data from the first phase III study (PATENCY-1) on its lead candidate, vonapanitase (formerly known as PRT-201), in patients with ...

Proteon Therapeutics Inc.’s PRTO shares have gained around 7.8% after announcing encouraging results from a long-term analysis of follow-up data from a phase II study on vonapanitase last week. The ...

WALTHAM, Mass. and NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (“Proteon”) (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical ...

Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company WALTHAM, Mass.

(Reuters) - Proteon Therapeutics Inc said on Tuesday that its experimental chronic kidney disease drug failed to meet the main goal in a late-stage study, sending its shares plunging about 75 percent ...

* Proteon therapeutics inc- enrollment in patency-2 trial is expected to complete in q1 of 2018 * Proteon therapeutics inc- proteon expects to report top-line data in q1 of 2019 * Proteon therapeutics ...

Partners extend existing contract for manufacture of vonapanitase to 2029 as ongoing Phase 3 trial nears completion Lonza Pharma & Biotech successfully scaled up a lab process at their Microbial ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Proteon Therapeutics Inc., a pharmaceutical company founded ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Proteon Therapeutics Inc. (NASDAQ: PRTO) shares were ...

Please provide your email address to receive an email when new articles are posted on . Proteon Therapeutics Inc. announced positive results from a long-term analysis of more than three years of ...

Proteon Therapeutics priced its initial public offering at $10 a share on Tuesday and closed at nearly that price — $10.03 — in first-day trading Wednesday. The pharmaceutical-development company, ...